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Abstract
Background:  Actinobacillus pleuropneumoniae is the causative agent of porcine contagious
pleuropneumonia, a highly contagious respiratory infection in pigs, and all the 15 serotypes are able
to cause disease. Current vaccines including subunit vaccines could not provide satisfactory
protection against A. pleuropneumoniae. In this study, the immunoproteomic approach was applied
to the analysis of extracellular and outer membrane proteins of A. pleuropneumoniae JL03 serotype
3 for the identification of novel immunogenic proteins for A. pleuropneumoniae.
Results:  A total of 30 immunogenic proteins were identified from outer membrane and
extracellular proteins of JL03 serotype 3, of which 6 were known antigens and 24 were novel
immunogenic proteins for A. pleuropneumoniae.
Conclusion:  These data provide information about novel immunogenic proteins for A.
pleuropneumoniae serotype 3, and are expected to aid in development of novel vaccines against A.
pleuropneumoniae.
Background
Actinobacillus pleuropneumoniae, a gram negative capsu-
lated rod bacterium, is the etiologic agent of a severe,
highly infectious and often fatal pleuropneumonia in
swine, which is distributed world wide and results in
severe losses in the swine industry. Based on capsular anti-
gens, 15 serotypes of A. pleuropneumoniae to date have
been documented, and all serotypes are capable of caus-
ing disease though differences in virulence have been
described [1]. Among these serotypes, serotype 3 is one of
the predominant serotypes in China [2].
So far, satisfactory protection has not been achieved in the
A. pleuropneumoniae vaccination field in spite of intensive
attempts made on inactivated whole-cell vaccines, live
avirulent vaccines, which showed partial protection
against challenges with homologous or heterologous
serotypes[3]. Although currently available subunit vac-
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cines contain important antigens, such as ApxI, ApxII and
ApxIII, produced in various combinations by the different
serotypes of A. pleuropneumoniae[4], they could not pro-
vide complete protection against A. pleuropneumoniae[3].
Thus identifying more conserved antigens is necessary for
the development of novel vaccines, and in this study the
immunogenic proteins of JL03 serotype 3 will be investi-
gated to provide data for novel vaccine development.
Extracellular proteins (ECPs) and OMPs in pathogens are
involved in colonization, adhesion to and invasion of
host cells. They interact directly with the host immune sys-
tems while playing crucial roles in the course of infec-
tions. Thus it is feasible to identify the important vaccine
candidates from these sub-fractions. Currently, the immu-
noproteomic approach is a powerful tool to systematically
identify immunogenic proteins from pathogens, and
novel antigens have been successfully discovered from S.
streptococcus [5], B. anthrax [6] and S. flexneri [7] by this
approach from bacterial subfractions, such as outer mem-
brane proteins.
Recently, Chung et al. performed systematically proteomic
analysis on OMPs of A. pleuropneumoniae serotype 5b, and
47 OMPs were identified[8], and there have been attempts
but they are not recent and, therefore, could not use a pro-
teomics approach. And no attempt has been reported so
far in analysis of the ECPs of A. pleuropneumonae. The com-
plete genome sequence of A. pleuropneumonia JL03 pro-
vided an essential database for applying
immunoproteomic approach to JL03. In the present
study, we report this approach to JL03 for the first time
which involved the identification of immunogenic pro-
teins from its OMPs and ECPs.
Results and Discussion
2-DE profile of the ECPs and OMPs, immunoblotting 
analysis and identification of immunogenic proteins
In the present study, linear immobilized pH gradient
strips (310 L IPG 13 cm) and 10% SDS-PAGE gels were
used for the prepared samples separation. Figure 1A and
1B show the 2-DE profile of OMPs and ECPs of A. pleurop-
neumoniae  JL03. The 2-DE and immunoblotting were
repeated three times and the results were reproducible. A
total of 110 spots and 98 spots were detected on the silver-
stained gels of OMPs and ECPs respectively by the soft-
ware ImageMaster v 6.01. After immunoblotting analysis
with convalescent sera, 28 immunoreactive spots from
OMPs (Figure 1A and 1C) were identified, and they repre-
sented 17 proteins. Chung et al. recently identified 47 OM
proteins from A. pleuropneumoniae 5b with an optimized
extraction protocol based on the sucrose-density gradient
which yielded preparations highly enriched for OM pro-
teins and lipoproteins[8], and 10 of the 47 OM proteins
were identified as immunogenic proteins in this study. In
addition, Rhonda et al. recently demonstrated the sucrose-
density gradient extraction of outer membranes in Campy-
lobacter jejuni produced purer sample than carbonate
extraction [9] that was applied in this study. So further
study needs to be tried on immunoproteomic analysis of
other serotypes of A. pleuropneumoniae with the optimized
OMP extraction protocol of Chung et al. for search of
more immunogenic OMPs. All the 19 immunoreactive
spots from ECPs (Figure 1B and 1D) that represented 16
proteins were identified whereas no specific immunoreac-
tive protein spot was observed from OMPs and ECPs
using control sera. The detailed Peptide Mass Fingerprint-
ing (PMF) results of the immunoreactive proteins are
listed in supplemental table S1 [see additional file 1].
Overall, values of gel estimated pI and MW are matched
well with their theoretical ones but some discrepancies
still exist. Similar migration for several proteins has been
observed in proteomic analysis of other pathogens previ-
ously[10,11]. This might be due to the presence of natural
isoforms, posttranslational processing, and/or modifica-
tion, or an artifact caused by sample preparation.
All identified proteins were predicted by PSORTb 2.0, 10
proteins are annotated as periplasmic proteins, 7 are
OMPs, 2 are extracellular proteins, 2 are cytoplasmic pro-
teins, 1 is cytoplasmic membrane protein, and 8 are
unknown. The detailed functions of the identified immu-
noreactive proteins are shown in supplemental table S1
[see additional file 1] according to the results predicted by
COGnitor.
Interestingly, 3 immunogenic proteins, MomP1, MomP2
and elongation factor Tu were identified from OMPs and
ECPs simultaneously, which might be due to outer mem-
brane vesicles released in the milieu [12], from which
outer membrane proteins have been identified success-
fully from E. coli and A. pleuropneumoniae[8,13], and to
dual localization of elongation factor Tu [14].
Characterization of identified immunogenic proteins
Our immunogenic approach led to the identification of 6
known antigens of A. pleuropneumoniae, namely MomP1,
MomP2, ApxIIA, ApxIIIA, Na+-translocating NADH-ubiq-
uinone oxidoreductase subunit A (NqrA) and outer mem-
brane ferric hydroxamate receptor (FhuA)[15,16]. And
other well-known antigens, like ApxI, ApxIV, outer mem-
brane lipoprotein A (OmlA), outer membrane protein
precursor (PalA) and Transferrin binding proteins (Tbp)
proteins could not be detected in the present study. ApxIV
is only induced in vivo and JL03, serotype 3 strain, can not
produce ApxI, and therefore we could not detect ApxI and
ApxIV. Tbp proteins are expressed under iron limited con-
ditions and the cells we collected were not prepared under
such conditions. So Tbp proteins did not appear in our
results. The highly hydrophobic nature of OmlA and PalA
might cause their loss during extraction procedure. PalABMC Microbiology 2009, 9:172 http://www.biomedcentral.com/1471-2180/9/172
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has been proved to be detrimental when used in vac-
cines[17], and thus we should be cautious about similar
immunogenic proteins while applying them to vaccine
development.
In addition, we found 16 immunogenic proteins that had
an significant sequence similarity to known proteins, and
they have already been shown immunogenic in certain
pathogenic bacteria, but not in A. pleuropneumoniae
before, namely D15/OmpD, LppB, FrdA, MDH, FepA,
FrpB, TufB, PotD, GapA, ZnuA, TIG, DegP, TufB, PsaA,
FkpA and PTA. The homolog D15/Omp85 is an essential
component for outer membrane biogenesis and OMP
assembly [18,19]. The immunogenicity of D15 and its
homolog Omp87 has been demonstrated in Haemophilus
ducreyi  [20] and Pasteurella multocida [21] respectively.
Furthermore, antibodies against the COOH-terminal
"surface antigen" domain of D15 are protective against
2-DE profile of ECPs and OMPs and immunoblot Figure 1
2-DE profile of ECPs and OMPs and immunoblot. 2-DE profile of OMPs (A) and ECPs (B) from A. pleuropneumoniae JL03 
strain. Preparative gel stained with Silver Nitrate. Immunoblot of OMPs and ECPs from convalescent sera (C) and (D). The gel 
spots were encoded using a letter followed by the protein number, which was assigned based on their similar locations on dif-
ferent gels/membranes.BMC Microbiology 2009, 9:172 http://www.biomedcentral.com/1471-2180/9/172
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Haemophilus influenzae infection in animal models [22].
The immunoreactive spot O16 was homologous to LppB
and shared 49% sequence identity with LppB of H. somni
that has been shown as an immunodominant protein
[23], and the gene lppB of A. pleuropneumoniae is impor-
tant for survival during infection[24]. Fumarate reductase
(FrdA) was found to be involved in biosynthesis of flag-
ella and cell motility, which might contribute to an signif-
icantly attenuated A. pleuropneumoniae [25] and loss of the
ability in colonizing in the gastric mucosa in Helicobacter
pylori[26] after frdA genes were inactivated. Furthermore,
Joseph et al. described FrdA as an antigen in Brucella abor-
tus [27]. FepA, FrpB and HbpA are important components
in several ABC transport pathways for obtaining iron or
regulating iron utilization in vivo or vitro. The immuno-
genic activity of FepA and FrpB was shown in Klebsiella
pneumoniae  [28] and Neisseria meningitides [29] respec-
tively, and HbpA was widely conserved and served as an
antigen in Leptospira interrogans[30]. Moreover, homolo-
gous analysis of these proteins at NCBI revealed a high
level identity (>98%) with the sequenced serotype 1, 5
and 7 strains respectively. These suggest that they might be
new common antigens for A. pleuropneumoniae. High-
affinity zinc uptake system protein ZnuA precursor, was
essential of B. abortus for intracellular survival and viru-
lence in mice[31] and shown immunogenic in Streptococ-
cus suis[5]. PsaA is needed for the adherence of
pneumococcal cells and antibodies to PsaA contributed to
reduce the nasopharyngeal colonization of challenged
pneumococcal cells [32,33]. DegPs, a member of the
widely conserved HtrA family of serine proteases, were fre-
quently identified as antigens in other pathogens, such as
B. abortus [34] and Chlamydia trachomatis [35]. Besides,
trigger factor (TIG) has been demonstrated to be an excel-
lent candidate for vaccination against Brucella melitensis
[36] and a virulence-related protein in Listeria monocy-
togenes [37], and similar findings were described about
malate dehydrogenase (MDH) of Candida albicans [38]
and spermidine/putrescine-binding periplasmic protein
(PotD) of Streptococcus pneumoniae [39]. Glyceraldehyde
3-phosphate dehydrogenase (GapA) has been proven to
be antigenically conserved proteins, suggesting potential
for vaccines in several microorganisms [40]. Homologous
protein of translation elongation factor EF-Tu (TufB), a
very abundant protein, had been detected in immunolog-
ical researches of other bacteria, such as C. trachomatis[41]
and Shigella flexneri[7]. The periplasm of gram-negative
bacteria is well equipped with ATP-independent chaper-
ones and folding catalysts, including peptidyl-prolyl iso-
merases (FkpA). It is reported recently that FkpA was
found to be immunogenic in Bordetella pertussis[42]. Phos-
phate acetyltransferase (PTA), an enzyme that catalyzes
the reversible transfer of the acetyl group from acetyl
phosphate to coenzyme A plays a major role in the energy-
yielding metabolism[43] and recently has been reported
to be immunogenic in S. suis[5].
It is notable that CbiK, IlvG, FepB, AfuC, FatB, GGBP,
CysG and Ttg2D, are reported to be immunogenic pro-
teins for the first time in this study whose functions have
been biologically demonstrated in some bacteria. Putative
periplasmic binding protein CbiK is involved in the
uptake of Ni2+, a cofactor required for urease activity that
is important in pathogenesis of pleuropneumonia [44].
The ilv gene of Brucella suis has been identified as a viru-
lence gene[45], and its product, acetohydroxyacid syn-
thase, catalyzes the first common step in the biosynthetic
pathway of the branched-amino acids such as leucine, iso-
leucine, and valine. Iron is essential for bacterial growth,
especially for A. pleuropneumoniae in invading and repro-
ducing in porcine respiratory tract where iron is limited.
Iron-restriction is an important signal that regulates
expression of many genes including some coding for viru-
lence factors[46]. FepB, AfuC and FatB are components of
known iron transport pathways, and the immunogenic
reactivity of these proteins in this study indicates that
these iron-uptake proteins might be potential candidates
for development of subunit vaccines. D-Galactose/D-glu-
cose binding protein (GGBP) is a bacterial periplasmic
protein, an initial component for both chemotaxis
towards galactose and glucose and active transport of the
two sugars in Escherichia coli[47]. The crystal structure of
uroporphyrinogen-III methylase (CysG) from Thermus
thermophilus has been reported[48] and the cysG gene of
Salmonella typhimurium is involved in synthesis of both
cobalamin (B12) and siroheme[49]. The ttg2D gene
encodes a periplasmic component of an ABC-type trans-
port system related to resistance to organic solvents, and
Ttg proteins of Pseudomonas putida and  N. meningitidis
were verified to participate in the uptake of L-gluta-
mate[50].
Novel vaccine candidates need to be highly conserved
between strains and so that they induce cross-protection
against A. pleuropneumoniae. Recently Goure et al. have
identified A. pleuropneumoniae genes that are conserved
among all 15 serotypes by comparative genomic hybridi-
zation[51]. Of these conserved genes, the genes encoding
proteins MomP1 (OMP P5), MomP2 (OMP P5), D15
(OmpD), LppB, PotD, FkbP and FrpB were observed in
our results. Besides, NqrA has been demonstrated to be
common to all serotypes[15]. Thus these conserved pro-
teins could potentially induce protection against a wide
variety of strains and are attractive vaccine candidates.
Conclusion
In conclusion, the 2DE in combination with Western blot
is a specific and powerful method to discover novel anti-
gens from bacterial pathogens. In this study, the identifiedBMC Microbiology 2009, 9:172 http://www.biomedcentral.com/1471-2180/9/172
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immunogenic proteins from ECPs and OMPs may be sig-
nificant for the development of new efficient vaccine
against A. pleuropneumoniae. The protective efficacy of the
identified immunogenic proteins either by alone or in dif-
ferent combinations remains to be evaluated in further
studies. The data of this study are expected to aid in devel-
opment of novel vaccines against A. pleuropneumoniae. The
present study has focused on 2DE analysis coupled with
Western blotting.
Methods
Bacterial strains and culture conditions
A. pleuropneumoniae JL03 [52], a Chinese field isolate
strain of serotype 3, was used for this study. Bacteria were
routinely maintained on tryptic soy agar (Difco Laborato-
ries, Detroit) containing 10% bovine calf serum and
0.01% nicotinamide adenine dinucleotide (NAD) and
cultured in brain heart infusion (BHI, Difco Laboratories,
Detroit) media containing 0.01% NAD in a rotary incuba-
tion shaker running at 180 rev min. For protein extrac-
tions, overnight bacterial cultures were diluted 1:100 in 1
L BHI broth and grown aerobically at 37°C at 180 rev
min. Three independent cultures at different days were
prepared for ECPs and OMPs preparation respectively.
Extracellular proteins sample preparation
Growth was stopped at the early exponentional phase at
an OD600 of ~0.4. Supernatant containing protease inhib-
itor cocktail (Roche, Mannheim, Germany) was collected
by centrifugation for 10 min at 7200 × g (Sigma 3K12, Nr.
12150) at 4°C and filtered with 0.22 μm membrane (Mil-
lipore, USA). The supernatant was then treated with 15%
TCA (Sigma Chemical) in ice for 30 min to precipitate
protein. The precipitate was collected by centrifugation at
10 000 × g for 20 min at 4°C. Then the precipitated pro-
tein was washed three times with ice cold acetone contain-
ing 0.1% DTT to remove traces of TCA, and acetone was
finally removed by speed vacuum treatment. Extracellular
proteins were solubilized with 7 M urea, 2 M thiourea, 4%
CHAPS, and 65 mM DTT. Protein concentration was
determined by the GE Healthcare 2-D Quant Kit (Piscata-
way, NJ, USA).
OMPs sample Preparation
OMPs were prepared according to Molloy et al [53], with
minor modifications. Briefly, cells were harvested in the
middle exponential phase (OD600, ~1.0) by centrifuga-
tion for 10 min at 7200 × g (Sigma 3K12, Nr. 12150) at
4°C, and then the pellets were washed twice with cold 50
mM Tris-EDTA (pH 7.5) containing protease inhibitor
cocktail (Roche, Germany) and subsequently the cells
were suspended in 10 ml 50 mM Tris-EDTA (pH 7.5) and
ruptured by sonication at 50 watts; pulse on, 3 sec.; pulse
off, 3 sec. (Sonorex Digital 10 P Sonicator Bandelin, Ber-
lin, Germany), till the value of OD600 decreased to 1/10 of
its origin. Unbroken cells and cellular debris were
removed by centrifugation at 6000 × g for 10 min. The
supernatant was diluted 10-fold with ice cold 0.1 M
Na2CO3 (pH 11), and stirred slowly on ice for 1 h. The
OMPs were pelleted by ultracentrifugation in a Beckman
Optima MAX ultracentrifuge (Palo Alto, CA, USA) at 100
000 × g for 1 h at 4°C. The supernatant was then dis-
carded, and the pellet was resuspended and washed in 50
mM Tris-EDTA (pH 7.5) twice. The pellet was collected by
centrifugation at 100 000 × g for 1 h at 4°C and subse-
quently solubilized in a lysis buffer (7 M urea, 2 M thiou-
rea, 4% CHAPS, 1% Triton X-100 and 65 mM DTT).
Protein concentration was determined by the GE Health-
care 2-D Quant Kit.
Preparation of convalescent sera
Bacteria JL03 were prepared as described above and the
cells were washed once with PBS before dilution. Five pigs
free of A. pleuropneumoniae were inoculated intratracheally
at dose of 1.0 × 107CFU/pig in PBS to prepare the conva-
lescent sera, and three pigs survived. Twenty days after the
first infection, the survivors were rechallenged with
another identical dose of JL03. Sera were collected a week
after the second inoculation and evaluated. Antibody titer
of mixed sera from survivors 1:512 was measured by IHA
kit (Lanzhou Bioproducts Factory, Lanzhou, China). Sera
were collected before inoculation as control sera. All ani-
mals were housed and maintained in isolation facilities in
accordance with the Animal Care and Use Committee
guidelines of Huazhong Agricultural University.
2-DE and immunoblotting analysis
IEF was performed with the IPGphor II™ system (GE
Healthcare, USA) and the Immobiline DryStrip™ IPG-
strips of 13 cm (linear 310 pH gradient) according to Gorg
et al[54]. The prepared ECPs and OMPs (150 μg/strip) was
mixed with rehydration buffer (7 M urea, 2 M thiourea,
2% w/v CHAPS, 1%w/v DTT, 0.5%v/v IPG buffer, 0.002%
w/v bromophenol blue). The ECPs and OMPs samples
were focused for 50 kVh and 75 kVh respectively. After
IEF, three gels were run as follows. The IPGstrips were
respectively equilibrated for 15 min with 10 mg/ml DTT
and 40 mg/ml iodoacetamide in equilibration buffer (6 M
urea, 2% w/v SDS, 30% v/v glycerol, 0.002% w/v
bromophenol blue, 50 mM Tris-HCl, pH 8.8). After equi-
libration, the second dimension electrophoresis was per-
formed on a 10% SDS polyacrylamide gel using Hoefer
SE600 Ruby (Amersham Biosciences). Proteins of one gel
were visualized by staining with silver nitrate (Bio Basic
Inc). And gel evaluation and data analysis were carried out
using the ImageMaster v 6.01 program (GE Healthcare,
USA).
Immunoblot was performed according to Mansfield [55].
Gels were blotted onto PVDF transfer membranesBMC Microbiology 2009, 9:172 http://www.biomedcentral.com/1471-2180/9/172
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(Hybond-P, 0.45 mm; Amersham Biosciences). The mem-
branes were blocked in 5% BSA in TBS +0.05%(v/v)
Tween 20 for 1 h at room temperature and probed with
the convalescent swine sera and control sera (1:1000), for
1 h at room temperature, and then were washed and incu-
bated with goat anti-porcine IgG (H+L) -HRP (1:5,000)
(Southern Biotech, Birmingham, AL, USA) for 1 h at room
temperature, followed by development with Supersignal
west pico chemiluminescent substrate (Pierce, Rockford,
IL, USA) and imaged on the Image Station 2000 MM
(Kodak, Rochester, NY, USA). All experiments were done
in triplicate.
In-gel digestion of proteins[5]
Protein spots of interest were excised from gels and
detained with 100 μl 30 mM potassium ferricyanide and
100 μl 100 mM sodium thiosulfate (at a ratio of 1:1). And
the gel pieces were shrunken with 50 μl acetonitrile and
then re-swollen with 5 μl of 25 mM ammonium bicarbo-
nate containing 10 ng of trypsin at 4°C for 30 min. In-gel
tryptic degradation was performed overnight at 37°C, fol-
lowed by three subsequent extractions. The pooled
extracts were lyophilized and reconstituted in 2 μl 0.1%
TFA v/v prior to MALDI-TOF MS analysis.
MALDI-TOF MS analysis and database searchs
The sample solution with equivalent matrix solution was
applied onto the MALDI-TOF target and prepared for
MALDI-TOF-MS analysis according to a previously
described procedure [56]. CHCA was used as the matrix.
MALDI-TOF spectra were calibrated using trypsin autodi-
gestive peptide signals and matrix ion signals. MALDI
analysis was performed by a fuzzy logic feedback control
system (Ultraflex αMALDI TOF/TOF system Bruker, Karl-
sruhe, Germany) equipped with delayed ion extraction.
PMF data were searched against the database of JL03 by
MASCOT licensed in-house and the NCBInr database
using the MASCOT program http://www.matrix sci-
ence.com.
Bioinformatics tools
COGnitor http://www.ncbi.nlm.nih.gov/COG/old/xog
nitor was applied to sort the identified proteins of A. pleu-
ropneumoniae  JL03 into functional categories. PSORTb
v.2.0 is accessible at http://www.psort.org/psortb/
index.html and applied to predict the subcellular location
of the identified proteins.
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